Brittany Lovely

The development of agents to address intolerance and acquired resistance to BTK inhibitors addresses 2 of the major unmet needs for patients with chronic lymphocytic leukemia.

Targeted treatment options for patients with HER2-mutant non–small cell lung cancer have been slow to reach benchmarks for approval given the limited patient populations harboring this disease characteristic.

Treatment decisions in the second-line setting for patients with HER2-positive metastatic breast cancer are not as cut-and-dried as deciding between which data have the best outcomes.

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and molecular profiling.

Do-Youn Oh, MD, PhD, highlights the nuances of the TOPAZ-1 trial data that signal new pathways forward for investigative efforts in advanced biliary tract cancers.

Patients with polycythemia vera, a myeloproliferative neoplasm associated with JAK2 mutations and overproduction of red blood cells, often require regular therapeutic phlebotomies to avoid thrombosis.

Early sensitivity to FGFR inhibition has improved outcomes for patients across tumor histologies; however, kinase domain mutations limit extended efficacy for select patients including those with intrahepatic cholangiocarcinoma or urothelial cancer.

In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the final overall survival data submitted did not demonstrate a strong enough benefit-risk ratio for duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies.

Blocking ligand interaction of HER2 and HER3 in patients with NRG1 fusion–positive tumors has demonstrated a clinically feasible avenue to improve outcomes with the novel agent zenocutuzumab.

Evidence-based decisions have leveraged the use of immunotherapy combination atezolizumab plus bevacizumab for patients who receive a diagnosis of hepatocellular carcinoma.

Belzutifan plus cabozantinib was well tolerated and demonstrated promising antitumor activity in patients with treatment-naïve advanced clear cell renal cell carcinoma.

High response rates and encouraging durability support RLY-4008 as a transformative treatment option for patients with FGFR inhibitor–naïve cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Trastuzumab deruxtecan continued to demonstrate a clinical benefit and tolerable safety profile for patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen.

The combination of the CDK4/6 inhibitor dalpiciclib plus letrozole or anastrozole reduced the risk of disease progression by 49% vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

DNA damage homologous recombination repair genotypic variants are not created equal.

Shaji Kumar, MD, and Jonathan Kaufman, MD, review the advances with translocations such as t(11;14), treating practices, and emerging markers in multiple myeloma.

Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma.

Stephen V. Liu, MD and Neal E. Ready, MD, PhD, discuss the new data with nivolumab plus ipilimumab in treatment-naïve NSCLC and provide commentary on treatment considerations for patients who are eligible to receive these regimens.

CDK4/6 inhibitors have carved out a substantial role in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer.

Recent data highlight the value of the newly approved indications for nivolumab plus ipilimumab and nivolumab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma.

New combinations and strategies are needed for patients with non–small cell lung cancer who progress after first-line chemoimmunotherapy after results of a retrospective analysis showed modest efficacy with second-line chemotherapy.

EGFR C797X mutations have become a leading mechanism of acquired resistance following treatment with the third-generation EGFR inhibitor osimertinib, outpacing MET amplification.

Acquired resistance because of genetic alterations in the MET receptor has limited the efficacy of the EGFR inhibitor osimertinib in patients with non–small cell lung cancer. Investigators have sought to circumvent this barrier through targeting MET protein activity with the addition of the novel MET TKI, savolitinib.

Erika P. Hamilton, MD, shares how multidisciplinary collaboration between pathologist and breast oncologists is key to staying abreast of not only the classification-actionable HER2 mutations in metastatic breast cancer but also the evolving definition of expression.

Ignacio I. Wistuba, MD, explains how major pathological response and pathological complete response should be interpreted and their role as clinical end points.

Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates represent a promising development for this population.

The addition of pertuzumab to standard adjuvant therapy of trastuzumab and chemotherapy continued to reduce the risk of disease recurrence or death for patients with HER2-positive early breast cancer according to data from the third interim overall survival analysis of the phase 3 APHINITY trial.

Digital health solutions have the potential to improve outcomes via remote symptom monitoring, increase patient/physician communication, and improve patient education.

Patient-reported outcomes from the phase 3 SPARED trial showed that despite consistency in global health status, patients experienced worse nausea and appetite loss with dexamethasone-sparing approaches.